Skip to main content
Terug
Watch Compare

Estrella Immunopharma, Inc.

Datakwaliteit: 83%
Ook genoteerd als ESLAW Nasdaq
ESLA
Nasdaq Manufacturing Chemicals
€ 1,83
▼ € 0,09 (-4,69%)
Marktkapitalisatie: 78,08 M
Prijs
€ 1,83
Marktkapitalisatie
78,08 M
Dagbereik
€ 1,70 — € 1,97
52-Weeksbereik
€ 0,78 — € 3,15
Volume
118.869
Openen € 1,97
50D / 200D Gem.
€ 1,15
58,76% above
50D / 200D Gem.
€ 1,32
38,80% above

Quick Summary

Belangrijkste Punten

Negative free cash flow of -1,79 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,15
Interest CoverageN/A

Waardering

PE (TTM)
-5,98
Onder sectorgemiddelde (-1,98)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (44 peers)
Metriek Aandeel Sector Mediaan
P/E -6,0 -2,0
P/B — 5,1
ROE % — -51,0
Net Margin % — -150,2
Rev Growth 5Y % — 9,3
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -13,06 M
ROE N/A ROA -401,70%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -1,79 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,15
Interest Coverage N/A Asset Turnover N/A
Working Capital -11,34 M Tangible Book Value -9,84 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5,98 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -2,29%
Market Cap 78,08 M Enterprise Value 76,45 M
Per Share
EPS (Diluted TTM) -0,35 Revenue / Share N/A
FCF / Share -0,04 OCF / Share -0,04
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 13,67%
SBC-Adj. FCF -2,26 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2021 FY2022
Revenue — — — —
Net Income -13,06 M -4,43 M -247.718,0 -996.104,0
EPS (Diluted) -0,35 -0,12 — —
Gross Profit — — — —
Operating Income -13,06 M -4,43 M -249.146,0 -1,57 M
EBITDA — — — —
R&D Expenses 10,25 M 2,86 M — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense — — — —
Income Tax 838,0 63,0 0,0 80.648,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2021 FY2022
Total Assets 3,18 M 3,14 M 45,80 M 9,72 M
Total Liabilities 13,54 M 3,00 M 1,62 M 2,65 M
Shareholders' Equity -10,37 M 143.731,0 -1,01 M -2,26 M
Total Debt — — — —
Cash & Equivalents 1,38 M 916.916,0 478.868,0 40.802,0
Current Assets 1,68 M 1,64 M 616.034,0 52.427,0
Current Liabilities 13,54 M 3,00 M 73.154,0 1,07 M